BACKGROUND: Manipulation of immune checkpoints such as @entity4386 or @entity8395 with targeted antibodies has recently emerged as an effective anticancer strategy in multiple @entity5 . @entity242 are a heterogeneous group of diseases in need of more effective treatments. Different subtypes of soft tissue and @entity79 have been shown to express @entity8395 ligand. METHODS: We retrospectively analyzed a cohort of @entity1 (pts) with relapsed metastatic/unresectable @entity242 , who were treated with nivolumab provided under a @entity1 assistance program from the manufacturer. Pts underwent CT or PET/CT imaging at baseline and after at least four doses of nivolumab; RECIST 1.1 criteria were used for response assessment. RESULTS: Twenty-eight pts with soft tissue (STS, N  =  24) or @entity79 (N  =  4), received IV nivolumab 3  mg/kg every 2  weeks from July 2015. Median age was 57 (24-78), male:female ratio was 14:14; the median number of nivolumab cycles was eight. Eighteen pts concomitantly received @entity6219 at 400-800  mg daily. The most common side effect was grade 1-2 LFT elevations; grade 3-4 @entity137 occurred in five @entity1 ( @entity1960 , LFT elevations, @entity55 ). Twenty-four pts received at least four cycles. We observed three partial responses: one @entity511 , one @entity242 and one @entity421 (last two @entity1 on @entity6219 ); nine @entity1 had stable disease including three @entity1822 ; 12 @entity1 had progression of disease including 4 @entity1822 . Clinical benefit (response  +  stability) was observed in 50% of the evaluable @entity1 . CONCLUSIONS: These data provide a rationale for further exploring the efficacy of nivolumab and other checkpoint inhibitors in soft tissue and @entity79 .

Response to anti- @entity8395 therapy with nivolumab in metastatic XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity6219 :: ('MESH:C516667', 'Chemical') :: ['pazopanib'] @entity511 :: ('MESH:D002813', 'Disease') :: ['dedifferentiated chondrosarcoma'] @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcomas', 'epithelioid sarcoma', 'Sarcomas'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonitis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone sarcomas', 'bone sarcoma'] @entity1960 :: ('MESH:D003092', 'Disease') :: ['colitis'] @entity421 :: ('MESH:D012516', 'Disease') :: ['maxillary osteosarcoma'] @entity1822 :: ('MESH:D007890', 'Disease') :: ['leiomyosarcoma', 'leiomyosarcomas'] @entity8395 :: ('5133', 'Gene') :: ['PD-1'] @entity4386 :: ('1493', 'Gene') :: ['CTLA4']
@entity242 :: (MESH:D012509,Disease) :: ['sarcomas']
